Angel Biotech delivers another blow as it calls in administrators

Angel Biotechnology, which makes stem cells for medical research, delivered another blow to investors on Friday, calling for trading of shares to be suspended and sending the share price down over nine per cent.

Angel Biotechnology, which makes stem cells for medical research, delivered another blow to investors on Friday, calling for trading of shares to be suspended and sending the share price down over nine per cent.

The company, which in January announced that it was in discussions with a consortium of overseas organisations with the aim of establishing a strategic relationship between both parties in order to more effectively develop its contract manufacturing business, said Friday that these discussions have ended.

As a result the company has requested the immediate suspension of trading of its shares on AIM, pending clarification of its financial position.

"In view of its trading difficulties, the company intends to appoint administrators and a further announcement will be made as appropriate," was the comment made by the firm.

At the end of January the group said that the future of the group was dependent on it delivering both the proposed joint venture with MMH, but also on it entering a strategic relationship with another party.

It also acknowledged that it would be "extremely difficult" to raise funds through the market at the present time.

Angel, which makes stem cells for medical research, posted wider half year losses at £2.86m for the six month period ended September 30th 2012, most of which is attributable to a write back of accrued revenue and contract liabilities related to joint ventures. The company posted a loss of £241,000 the year before. Revenue for the period slipped to £1.07m from £1.4m previously.

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

How the stamp duty holiday is pushing up house prices
Stamp duty

How the stamp duty holiday is pushing up house prices

Stamp duty is an awful tax and should be replaced by something better. But its temporary removal is driving up house prices, says Merryn Somerset Webb…
25 Sep 2020
Can Rishi Sunak’s winter plan save the UK economy?
UK Economy

Can Rishi Sunak’s winter plan save the UK economy?

With his Winter Economic Plan, chancellor Rishi Sunak is hoping to support the economy through the dark months ahead as restrictions tighten again. Jo…
25 Sep 2020
The electric-car bubble could get an awful lot bigger from here
Renewables

The electric-car bubble could get an awful lot bigger from here

The switch to electric cars is driving a huge investment bubble. But that’s not necessarily a bad thing, says John Stepek. Fortunes will be made and l…
24 Sep 2020